<?xml version="1.0"?>
<Articles JournalTitle="Journal of Orthopedic and Spine Trauma">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Journal of Orthopedic and Spine Trauma</JournalTitle>
      <Issn>2538-2330</Issn>
      <Volume>10</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>04</Month>
        <Day>01</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Intravenous Injection of Tranexamic Acid in Patients with Pelvis or Acetabulum Fractures to  Reduce Blood Loss: A Double-Blind, Randomized, Controlled Trial</title>
    <FirstPage>9</FirstPage>
    <LastPage>14</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Reza</FirstName>
        <LastName>Zandi</LastName>
        <affiliation locale="en_US">https://orcid.org/0000 0002 0095 6745</affiliation>
      </Author>
      <Author>
        <FirstName>Alireza</FirstName>
        <LastName>Manafi-Rasi</LastName>
        <affiliation locale="en_US">http://orcid.org/0000-0001-6355-704X</affiliation>
      </Author>
      <Author>
        <FirstName>Mohammadreza</FirstName>
        <LastName>Minator Sajjadi</LastName>
        <affiliation locale="en_US">https://orcid.org/0000 0003 2081 7619</affiliation>
      </Author>
      <Author>
        <FirstName>Esmaeel</FirstName>
        <LastName>Yousefi-Hajivand</LastName>
        <affiliation locale="en_US">https://orcid.org/0000-0002-9337-0662</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>06</Month>
        <Day>06</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>03</Month>
        <Day>13</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: Despite their low incidence, pelvis and acetabular fractures have a high mortality rate due to
extensive hemorrhage. Tranexamic acid (TXA) is an antifibrinolytic drug that inhibits the production of
plasminogen. The aim of the current study is to evaluate the safety and efficacy of TXA use for blood loss
reduction and the need for blood transfusion in patients with fractures of the pelvis or acetabulum.
Methods: 108 patients were recruited from two tertiary care hospitals and assigned evenly either to the
intervention (TXA) or the control group. TXA group received 15mg/kg TXA 30 minutes before the fracture
reduction and fixation surgery. The number of transfused blood units before, during, and after the surgery
was recorded. Blood loss was assessed by calculation of estimated blood loss (EBL), collected blood with
drain, collected blood with suction, and weight of the used gauzes during the surgery. The time between
fracture occurrence and the surgery, the duration of the surgery, and the days of admission were assessed.
Results: The mean age was 39.49 &#xB1; 15.81, and 69.4% were female. 6 patients had pelvic, and 102 patients
had acetabulum fractures. The duration of the surgery was not significantly different. The time gap between
the reconstructive surgery and fracture occurrence was significantly higher in the TXA group (P = 0.032).
The mean postoperative hospitalization time was significantly lower among TXA group patients (P = 0.037).
The mean hemoglobin in the TXA group was significantly higher, postoperatively (P = 0.028). The mean
EBL, the blood volume collected by suction or drain, the weight of the consumed gauze during the surgery,
and the number of transfused blood units were significantly lower in the TXA group. The transfusion rate
was significantly lower in patients with a shorter time gap between fracture occurrence and reduction
surgery (P = 0.021).&#xA0;
Conclusions: TXA can decrease blood loss, the transfused blood units during and after the operation, and&#xA0;hospital admission days. Moreover, it did not increase the chance of pulmonary thromboembolism or deep&#xA0;vein thrombosis in the patients receiving tranexamic acid; thus, it can be assumed as a safe and efficient
drug in patients with acetabulum or pelvis fractures.</abstract>
    <web_url>https://jost.tums.ac.ir/index.php/jost/article/view/505</web_url>
    <pdf_url>https://jost.tums.ac.ir/index.php/jost/article/download/505/358</pdf_url>
  </Article>
</Articles>
